title: Rasburicase for the treatment of tumor lysis in hematological malignancies.
abstract: Tumor lysis syndrome (TLS) is a common oncologic emergency in patients with hematological malignancies sensitive to cytotoxic treatment that present a high proliferative rate. High proliferative cancer rate, high sensitivity of cytotoxic treatment and renal failure represent risk factors for development of TLS. TLS is also responsible for several electrolytic alterations, such as hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia. There are different established therapeutic options for the treatment of TLS such as hydration, allopurinol and rasburicase. Rasburicase reduces uric acid levels within 4 h, both in pediatric and adult patients, catalyzing the oxidation of uric acid into allantoin, rapidly excreted by the kidneys. Rasburicase is well tolerated and was approved in the EU and in the USA for the management of acute hyperuricemia.
authors.affiliation: Department of Internal Medicine & Systemic Pathologies, Ospedale Cannizzaro, Viale Messina, 829-95125 Catania, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Malaguarnera
authors.forename: Maria
authors.initials: M
authors.lastname: Giordano
authors.forename: Mariano
authors.initials: M
authors.lastname: Malaguarnera
mesh_terms: D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D015275:Tumor Lysis Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014503:Urate Oxidase / Q000494:pharmacology / Q000627:therapeutic use*; D014527:Uric Acid / Q000378:metabolism
chemical_list: C469709:rasburicase; D014527:Uric Acid; D014503:Urate Oxidase